PubMed Health⌕ Search

Biomedical subjects

N Chariatte

Publications and source records attributed to N Chariatte.

10 recordsLinked to original sources

[Tolerability and pharmacokinetics of an intravenous immunoglobulin preparation in immunologically normal subjects and tolerability in patients with hypogammaglobulinemia resulting from chronic lymphatic leukemia].

Tolerance, clinical effects and kinetics of an unmodified immunoglobulin preparation for intravenous use were investigated in 4 patients with advanced chronic lymphocytic leukemia. Previously, good tolerance of the preparation had been found in 49 immunologically normal patients. The four patients with secondary humoral immunodeficiency received doses of 140-360 mg IgG/kg per infusion as outpatients at monthly intervals. With one exception, no acute infections (pneumonitis), as commonly seen before, were observed during the observation time of 24 to 68 weeks, and the pre-existing chronic infections (bronchitis, sinusitis etc.) remained compensated without antibiotics. In all four patients tolerance of the preparation was good. In all cases of hypogammaglobulinemia a dose-dependent increase in the serum IgG concentration was observed immediately after the infusion. However, persistence of the serum IgG increase showed considerable interindividual differences. The half life of the tetanus and HBs antibodies (21.7 to 34.4 and 19.7 to 25.7 days respectively) found in 4 healthy volunteers is within the biological range. This indicates an unmodified structure of the antibodies of the IgG class contained in the preparation used.

Adult↗

Activity of intravenous immune globulins against Klebsiella.

Seven commercial intravenous immune globulin (IVIG) preparations and an experimental hyperimmune globulin (Klebsiella immune-IVIG) were analyzed for antibody levels to Klebsiella capsular polysaccharides, opsonic activity, and protective capacity against Klebsiella. With one exception, all IVIGs reacted immunologically with the various capsular antigens, although titers between the preparations varied considerably. Klebsiella immune-IVIG possessed substantially higher titers (32-fold to 128-fold) than the commercial preparations. Only the hyperimmune globulin was capable of promoting the phagocytosis and killing of six Klebsiella test strains. When prophylactically administered, a commercial IVIG afforded significant protection (P less than 0.01) against fatal experimental Klebsiella sepsis only at a dose of 500 mg/kg. Klebsiella immune-IVIG provided a similar level of protection at a dose of 5 mg/kg. Whereas the commercial IVIG was ineffective when used therapeutically, the hyperimmune globulin was highly protective. Combined antibiotic-immunoglobulin therapy was most effective at reducing mortality.

Animals↗

Report of a working group for the European Pharmacopoeia. Collaborative assay on human albumin of different origin.

A collaborative assay was conducted by 9 laboratories on 31 samples of human albumin which were in clinical use. It was the object of the study to establish test systems which would differentiate between albumins of venous or placental origin. The properties examined for this purpose were: appearance, total protein, haem, polymers, alkaline phosphatase and blood group substances. Additional tests such as for beta-thromboglobulin and citrate were included; pyrogenicity, however, was excluded because this was under study for all plasma proteins at that time. Results obtained were in satisfactory agreement both between laboratories and between samples. They, therefore, enabled the verification of a number of correlations in the test systems. The evaluation did not allow, however, the differentiation of the samples in relation to their origin. The results were, therefore, regarded as a tool to define the upper limits of acceptance for human albumins corresponding to the quality prescribed by the European Pharmacopoeia.

ABO Blood-Group System↗

[Effect of the liver protecting compound ES 914 on D-galactosamine induced experimental hepatitis in the rat].

The i.p. application of 400 mg/kg D-galactosamine to rats induces liver damage which histologically resembles hepatitis. As also shown in the present investigation, the transaminases SGOT and SGPT in the serum of the damaged animals strongly increase already within 24 h. In the present investigation part of the animals (rats) was treated with 15, 30, 60, 125, 250 and 500 mg/kg of a new hepatoprotective preparation alpha,alpha-dithio-dicapronic acid (ES 914, Lipexal Berna) 2 h before and 6 h after the application of the liver damaging substance D-galactosamine (dose 400 mg/kg). ES 914 was applied p.o. whereas D-galactosamine was injected i.p. The transaminases were estimated at the beginning of the experiments as well as 24 h after the injection of D-galactosamine. The statistical evaluation of the results showed an increasing protective effect depending on the increasing dosage of the preparation ES 914. The protective effect begins at the latest with the dose of 30 mg/kg ES 914 and with 60 mg/kg it is highly significant (p less than or equal to 0.001). With a dosage of 500 mg/kg ES 914 the increase of SGOT and SGPT values is virtually abolished.

Alanine Transaminase↗